GENEVA--(BUSINESS WIRE)--iOnctura SA, a clinical-stage oncology company targeting key resistance mechanisms in solid tumors, announced today that it will present Phase Ib data on its lead pipeline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback